Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEISMiC-C
2023-507243-11-02Phase 2Completed
- Sponsor
- Windtree Therapeutics, Inc.
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised trial in cardiogenic shock comparing Istaroxime with Placebo (2 arms). Primary endpoint: Systolic blood pressure area under the curve from start of infusion to 6 hours. Started Dec 2024; status: completed.
02
Drugs
istaroxime
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on 2023-507243-11-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507243-11-02.